Generated: May 23, 2017
|Title:||Generation of therapeutic microfoam|
|Abstract:||Improved therapeutic sclerosing microfoams and methods and devices for making them are provided that have advantage in producing a consistent profile injectable foam with minimal input by the physician yet using high volume percentages of blood dispersible gases, thus avoiding use of potentially hazardous amounts of nitrogen.|
|Inventor(s):||Osman; Tariq (London, GB), Shilton-Brown; Sheila Bronwen (Brentwood, GB), Wright; David Dakin Iorwerth (High Wycombe, GB), Harman; Anthony David (Henley-on-Thames, GB), Boorman; Timothy David (Frinton on Sea, GB)|
|Assignee:||BTG International Limited (London, GB)|
|Filing Date:||Jun 18, 2009|
|Claims:||1. A method for producing a microfoam suitable for use in sclerotherapy of blood vessels characterized in that it comprises passing a mixture of a physiologically acceptable blood dispersible gas, wherein said gas comprises at least 50% vol/vol carbon dioxide, and an aqueous sclerosant liquid through one or more passages, the ratio of gas to liquid being controlled such that a microfoam is produced having a density of between 0.07 g/ml to 0.19 g/ml and has a half-life of at least 2 minutes. |
2. A method as claimed in claim 1 the gas/liquid ratio in the mixture is controlled such that the density of the microfoam is 0.09 g/mL to 0.16 g/mL.
3. A method as claimed in claim 1 characterized in that at least 50% by number of the gas bubbles of 25 .mu.m diameter and above are of no more than 200 .mu.m diameter and at least 95% of these gas bubbles are no more than 280 .mu.m diameter.
4. A method as claimed in claim 1 characterized in that at least 50% by number of the gas bubbles of 25 .mu.m diameter and above are of no more than 150 .mu.m diameter and at least 95% of these gas bubbles are no more than 250 .mu.m diameter.
5. A method as claimed in claim 1 characterized in that the mixture of gas and sclerosant liquid is in the form of an aerosol, dispersion of bubbles in liquid or macrofoam.
6. A method as claimed in claim 1 characterized in that the ratio of gas to liquid used in the mixture is 1 gram sclerosant liquid to from 6.25 to 14.3 volumes of gas at standard temperature and pressure.
7. A method as claimed in claim 1 characterized in that the physiologically acceptable blood dispersible gas comprises a major proportion of carbon dioxide and/or oxygen.
8. A method as claimed in claim 1 characterized in that the aqueous sclerosant liquid is a solution of polidocanol or sodium tetradecylsulfate (STS) in an aqueous carrier.
9. A method as claimed in claim 8 characterized in that the carrier comprises a saline solution.
10. A method as claimed in claim 1 characterized in that the mixture of gas and liquid is passed through the same passage or passages a number of times.
11. A method as claimed in claim 1 characterized in that the gas is pressurized at 0.1 to 9 bar over atmospheric pressure.
12. A method as claimed in claim 11 characterized in that the gas is pressurized at 0.1 to 3 bar over atmospheric pressure.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.